Industrials Author：Notrice May 11, 2024 06:25 PM (GMT+8)

EqualOcean has learned that Synaura(虹摹生物)recently successfully completed a pre-Series A financing round of nearly CNY 100 million. This round of financing was led by Zhongjin Capital's CICC Qide Fund(中金启德基金) and followed by Maotai Investment(茅台基金). The new funds will be used for new product research and development, laboratory construction, industrialization, and commercial promotion, injecting new momentum into Synaura's innovative development in the HMO field.

Milk powder / milk

Founded in February 2022, Synaura's product applications cover various fields such as biomedicine, agriculture, and health food. Among them, HMO is the core product of Synaura in the field of nutrition and health. As a leader in China's domestic HMO field, Synaura leads the future trend of nutrition with independently developed HMO products. Its HMO products are known for their high purity, low impurities, and odorlessness, setting a new benchmark for health and nutrition. With advanced research and development technology and precise fermentation processes, Synaura's products meet the innovative needs of customers and consumers' demands for high-quality nutrition.

HMO, also known as human milk oligosaccharides, is a component naturally present in breast milk. Its content is highest in colostrum, around 20-25g/L, and about 5-20g/L in mature milk, making it the third-largest solid component after lactose and lipids.

According to EqualOcean, on October 7, 2023, the National Health Commission of China announced the approval of the domestic use of two HMO components, 2'-Fucosyllactose and Lacto-N-neotetraose, which attracted industry attention and marked the beginning of a new round of formula upgrades.

As a widely recognized important nutritional element in breast milk research, the approval of HMO use undoubtedly injects vitality into the entire domestic infant formula industry. This policy not only provides opportunities for domestic dairy companies to improve their category layout but also serves as an important breakthrough for the differentiation and high-end development of domestic children's milk powder brands.

Although the prospects for the HMO track are promising, dairy companies face many challenges in following HMO formulations. From research and development support, formula registration, production line adjustments to product landing, the lengthy cycle forces dairy companies with insufficient strength to stop. However, in the fiercely competitive market, brands that break through first by laying out early and quickly occupying industry high points.

Synaura is the only domestic enterprise among the first batch of HMO suppliers approved by the National Health Commission, and also the first Chinese enterprise to obtain GRAS certification in the field of HMOs, as well as the first Chinese HMO company in the process of GRAS certification and novel food authorization.

In the future, with the support of various shareholders, Synaura will accelerate the construction of research and innovation capabilities, focus on the development of HMOs and new pipelines, further enhance the professional influence of domestic HMOs, continuously cultivate new productivity, and help the dairy industry achieve high-quality development.